High-performance liquid chromatographic method for sensitive determination of the alkylating agent CB1954 in human plasma

被引:4
作者
Anderson, D
Ferry, DR
Knox, RJ
Andrews, SJ
Downes, AJ
Kerr, DJ
Seymour, LW [1 ]
机构
[1] Univ Birmingham, Inst Canc Studies, CRC, Birmingham B15 2TA, W Midlands, England
[2] Enzacta Ltd, Salisbury SP4 0JQ, Wilts, England
来源
JOURNAL OF CHROMATOGRAPHY B | 1999年 / 731卷 / 02期
关键词
CB1954; alkylating agents;
D O I
10.1016/S0378-4347(99)00245-5
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A high-performance liquid chromatography (HPLC) method is described for the measurement of the weak alkylating agent CB1954 in human plasma. CB1954 can be used as an innocuous prodrug designed for activation by bacterial nitroreductases in strategies of gene-directed enzyme-prodrug therapy, and becomes activated to a potent bifunctional alkylating agent. The HPLC method involves precipitation and solvent extraction and uses Mitomycin C (MMC) as an internal standard, with a retention time for MMC of 5.85+/-0.015 min, and for CB1954 of 10.72+/-0.063 min. The limit of detection for CB1954 is 2.9 ng/ml, and this compares favourably with systems involving direct analysis of plasma (limit of detection 600 ng/ml, approximately). The method is now being used for pharmacokinetic measurements in plasma samples from cancer patients entering phase I clinical trials of CB1954. Results using serial plasma samples from one patient are presented. The patient was treated intravenously with CB1954 (6 mg/m(2)), and plasma clearance of the drug showed biphasic kinetics with alpha half-life 14.6 min, and beta half-life 170.5 min. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:293 / 298
页数:6
相关论文
共 11 条
[1]   THE BIOACTIVATION OF 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) .1. PURIFICATION AND PROPERTIES OF A NITROREDUCTASE ENZYME FROM ESCHERICHIA-COLI - A POTENTIAL ENZYME FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) [J].
ANLEZARK, GM ;
MELTON, RG ;
SHERWOOD, RF ;
COLES, B ;
FRIEDLOS, F ;
KNOX, RJ .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (12) :2289-2295
[2]   NAD(P)H-QUINONE OXIDOREDUCTASE(1) (DT-DIAPHORASE) EXPRESSION IN NORMAL AND TUMOR-TISSUES [J].
BELINSKY, M ;
JAISWAL, AK .
CANCER AND METASTASIS REVIEWS, 1993, 12 (02) :103-117
[3]   Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954 [J].
Bridgewater, JA ;
Springer, CJ ;
Knox, RJ ;
Minton, NP ;
Michael, NP ;
Collins, MK .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) :2362-2370
[4]   PRODRUGS IN CANCER-CHEMOTHERAPY [J].
CONNORS, TA ;
KNOX, RJ .
STEM CELLS, 1995, 13 (05) :501-511
[5]   The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954 [J].
Drabek, D ;
Guy, J ;
Craig, R ;
Grosveld, F .
GENE THERAPY, 1997, 4 (02) :93-100
[6]   Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase [J].
Friedlos, F ;
Court, S ;
Ford, M ;
Denny, WA ;
Springer, C .
GENE THERAPY, 1998, 5 (01) :105-112
[7]   THE BIOACTIVATION OF 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) .2. A COMPARISON OF AN ESCHERICHIA-COLI NITROREDUCTASE AND WALKER DT DIAPHORASE [J].
KNOX, RJ ;
FRIEDLOS, F ;
SHERWOOD, RF ;
MELTON, RG ;
ANLEZARK, GM .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (12) :2297-2301
[8]   THE NITROREDUCTASE ENZYME IN WALKER CELLS THAT ACTIVATES 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB-1954) TO 5-(AZIRIDIN-1-YL)-4-HYDROXYLAMINO-2-NITROBENZAMIDE IS A FORM OF NAD(P)H DEHYDROGENASE (QUINONE) (EC-1.6.99.2) [J].
KNOX, RJ ;
BOLAND, MP ;
FRIEDLOS, F ;
COLES, B ;
SOUTHAN, C ;
ROBERTS, JJ .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (24) :4671-4677
[9]   IDENTIFICATION, SYNTHESIS AND PROPERTIES OF 5-(AZIRIDIN-1-YL)-2-NITRO-4-NITROSOBENZAMIDE, A NOVEL DNA CROSS-LINKING AGENT DERIVED FROM CB1954 [J].
KNOX, RJ ;
FRIEDLOS, F ;
BIGGS, PJ ;
FLITTER, WD ;
GASKELL, M ;
GODDARD, P ;
DAVIES, L ;
JARMAN, M .
BIOCHEMICAL PHARMACOLOGY, 1993, 46 (05) :797-803
[10]   SELF-IMMOLATIVE PRODRUGS - CANDIDATES FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY IN CONJUNCTION WITH A NITROREDUCTASE ENZYME [J].
MAUGER, AB ;
BURKE, PJ ;
SOMANI, HH ;
FRIEDLOS, F ;
KNOX, RJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (21) :3452-3458